Allakos (ALLK) News Today → get a piece of the profit from this land (From True Market Insiders) (Ad) Free ALLK Stock Alerts $1.44 -0.01 (-0.69%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)May 11, 2024 | marketbeat.comAllakos (NASDAQ:ALLK) Trading Down 7%Allakos (NASDAQ:ALLK) Shares Down 7%May 10, 2024 | finanznachrichten.deAllakos Inc.: Allakos Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 10, 2024 | finance.yahoo.comAllakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings PredictionsMay 10, 2024 | markets.businessinsider.comAllakos Buy Rating: Clinical Promise and Financial Stability Drive Positive OutlookMay 9, 2024 | investorplace.comALLK Stock Earnings: Allakos Meets EPS for Q1 2024May 9, 2024 | globenewswire.comAllakos Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 3, 2024 | finance.yahoo.comWith 55% ownership of the shares, Allakos Inc. (NASDAQ:ALLK) is heavily dominated by institutional ownersApril 24, 2024 | markets.businessinsider.comMarket Outperform Rating Reiterated for Allakos Amid Promising AK006 Clinical DevelopmentsApril 11, 2024 | marketbeat.comAllakos (NASDAQ:ALLK) Trading Down 3.3%Allakos (NASDAQ:ALLK) Trading Down 3.3%April 9, 2024 | investorplace.com3 Biotech Stocks to Dump Before They Go to ZeroMarch 20, 2024 | marketbeat.comAllakos Inc. (NASDAQ:ALLK) to Post FY2025 Earnings of ($0.61) Per Share, Leerink Partnrs ForecastsAllakos Inc. (NASDAQ:ALLK - Free Report) - Analysts at Leerink Partnrs dropped their FY2025 EPS estimates for shares of Allakos in a report released on Sunday, March 17th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of ($0.61) per share for the year, down fromMarch 19, 2024 | markets.businessinsider.comHold Rating on Allakos Amidst Cautious Optimism for AK006 ProgramMarch 17, 2024 | marketbeat.comShort Interest in Allakos Inc. (NASDAQ:ALLK) Increases By 9.1%Allakos Inc. (NASDAQ:ALLK - Get Free Report) was the recipient of a significant growth in short interest in February. As of February 29th, there was short interest totalling 5,500,000 shares, a growth of 9.1% from the February 14th total of 5,040,000 shares. Based on an average daily trading volume, of 1,640,000 shares, the short-interest ratio is presently 3.4 days.March 16, 2024 | finance.yahoo.comAllakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4March 15, 2024 | markets.businessinsider.comHold Rating on Allakos Amidst Clinical Pivots and Prospective AK006 DevelopmentsMarch 15, 2024 | markets.businessinsider.comBuy Rating Maintained for Century Therapeutics with Increased Price Target Amid Promising Trials and Strong FinancialsMarch 15, 2024 | markets.businessinsider.comTD Cowen Remains a Hold on Allakos (ALLK)March 14, 2024 | investorplace.comALLK Stock Earnings: Allakos Misses EPS for Q4 2023March 14, 2024 | globenewswire.comAllakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 3, 2024 | marketbeat.comAllakos (ALLK) Scheduled to Post Earnings on MondayAllakos (NASDAQ:ALLK) will be releasing earnings on Monday, March 4, Yahoo Finance reports.February 26, 2024 | finanznachrichten.deAllakos Inc.: Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024February 26, 2024 | globenewswire.comAllakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024February 17, 2024 | finance.yahoo.comALLK Sep 2024 2.000 callFebruary 17, 2024 | finance.yahoo.comALLK Sep 2024 2.500 callFebruary 17, 2024 | finance.yahoo.comALLK Mar 2024 1.500 callFebruary 12, 2024 | finanznachrichten.deAllakos Inc.: Allakos Announces Publication Highlighting AK006 Mast Cell InhibitionFebruary 12, 2024 | finance.yahoo.comAllakos Announces Publication Highlighting AK006 Mast Cell InhibitionJanuary 28, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Allakos Inc. - ALLKJanuary 18, 2024 | finance.yahoo.comHere's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 WeeksJanuary 17, 2024 | marketbeat.comJMP Securities Cuts Allakos (NASDAQ:ALLK) Price Target to $3.00JMP Securities dropped their target price on shares of Allakos from $10.00 to $3.00 and set a "market outperform" rating for the company in a research report on Wednesday.January 17, 2024 | realmoney.thestreet.comAllakos price target lowered by 50c at Barclays, here's whyJanuary 17, 2024 | msn.comAllakos extends losses as analysts downgrade on Phase 2 setbackJanuary 17, 2024 | marketbeat.comAllakos (NASDAQ:ALLK) Lowered to Hold at Jefferies Financial GroupJefferies Financial Group lowered shares of Allakos from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $6.00 to $1.50 in a research note on Wednesday.January 16, 2024 | realmoney.thestreet.comAllakos just downgraded at Cantor Fitzgerald, here's whyJanuary 16, 2024 | realmoney.thestreet.comAllakos just downgraded at LifeSci Capital, here's whyJanuary 16, 2024 | finance.yahoo.comIs Allakos (ALLK) Stock Outpacing Its Medical Peers This Year?January 16, 2024 | marketbeat.comCantor Fitzgerald Lowers Allakos (NASDAQ:ALLK) to NeutralCantor Fitzgerald downgraded Allakos from an "overweight" rating to a "neutral" rating in a report on Tuesday.January 16, 2024 | investorplace.comWhy Is Allakos (ALLK) Stock Down 57% Today?January 16, 2024 | marketwatch.comAllakos to Cut Workforce by Half Amid Results from Lirentelimab TrialsJanuary 16, 2024 | marketwatch.comAllakos Shares Dive 61% Following Pivot from Lirentelimab After Trial ResultsJanuary 16, 2024 | finance.yahoo.comAllakos Announces a Restructuring to Focus on Development of AK006January 16, 2024 | msn.comElevai Labs, Allakos, TransCode Therapeutics among healthcare moversJanuary 16, 2024 | msn.comAllakos crashes on restructuring plansJanuary 16, 2024 | reuters.comAllakos to stop further development of skin disease drug, plans job cutsJanuary 16, 2024 | finance.yahoo.comAllakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary EndpointsJanuary 16, 2024 | marketbeat.comTrading was temporarily halted for "ALLK" at 06:01 AM with a stated reason of "News pending."December 20, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Allakos (ALLK) and Crinetics Pharmaceuticals (CRNX)December 19, 2023 | msn.comWilliam Blair Upgrades Allakos (ALLK)December 18, 2023 | markets.businessinsider.comAllakos Analyst Turns Bullish, Sees 'Significant Upside' If Study Results Are Positive Get Allakos News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Email Address Man who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.” (Ad)Man who spotted Apple at $1.49 says: "Buy These 6 AI Stocks." And these will be the biggest winners ALLK Media Mentions By Week ALLK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLK News Sentiment▼0.090.42▲Average Medical News Sentiment ALLK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLK Articles This Week▼11▲ALLK Articles Average Week Get Allakos News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Connect Biopharma News Today Adicet Bio News Today Relmada Therapeutics News Today BeyondSpring News Today PMV Pharmaceuticals News Today Oramed Pharmaceuticals News Today Citius Pharmaceuticals News Today Corvus Pharmaceuticals News Today Assertio News Today Cellectar Biosciences News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLK) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
